Standard BioTools Inc. (FLDM)
Standard BioTools Inc. develops and markets instruments, consumables, reagents, and software for biological research and clinical applications. Their integrated systems empower researchers and clinicians to accelerate discoveries and improve healthcare outcomes.
Company Overview
Standard BioTools Inc. (FLDM) empowers researchers and clinical labs with innovative analytical and preparatory systems, driving advancements in genomics, proteomics, and cell biology, offering a compelling investment in the future of precision medicine with a current market cap of $0.29B.
Investment Thesis
Standard BioTools Inc. presents a compelling investment opportunity within the life sciences tools sector. Despite a current negative P/E ratio of -3.76 and a profit margin of -99.6%, the company's gross margin of 47.9% indicates underlying strength in its core business. The investment thesis hinges on the company's innovative product portfolio and its strategic positioning in high-growth areas such as single-cell analysis and proteomics. Upcoming catalysts include potential partnerships with pharmaceutical companies to develop novel diagnostic assays and the expansion of its product offerings into new therapeutic areas. Key value drivers include increased adoption of its CyTOF and imaging systems in immuno-oncology research and the growing demand for its integrated fluidic circuits in genomics and proteomics applications. Successful execution of these strategies could drive significant revenue growth and improved profitability, making FLDM an attractive investment for long-term growth.
Key Highlights
- Market Cap of $0.29B reflects the company's current valuation in the market.
- Gross Margin of 47.9% indicates the profitability of the company's products and services before operating expenses.
- Beta of 1.14 suggests that the stock is slightly more volatile than the market.
- Negative P/E Ratio of -3.76 reflects current losses, but also potential for future earnings growth.
- The company's focus on single-cell analysis and proteomics positions it in high-growth segments of the life sciences tools market.
Competitors
Strengths
- Innovative product portfolio
- Strong expertise in microfluidics
- Established customer base
- Strategic partnerships with research institutions
Weaknesses
- Negative profitability
- High operating expenses
- Dependence on research funding
- Limited market share in some segments
Catalysts
- Upcoming: Potential partnerships with pharmaceutical companies for novel diagnostic assays.
- Ongoing: Expansion of product offerings into new therapeutic areas.
- Ongoing: Increased adoption of CyTOF and imaging systems in immuno-oncology research.
- Ongoing: Growing demand for integrated fluidic circuits in genomics and proteomics applications.
Risks
- Potential: Competition from larger, more established companies in the life sciences tools market.
- Potential: Technological advancements by competitors could render existing products obsolete.
- Ongoing: Dependence on research funding, which can be affected by economic conditions.
- Ongoing: Negative profitability and high operating expenses pose financial challenges.
Growth Opportunities
- Expansion in Single-Cell Analysis: The single-cell analysis market is experiencing rapid growth, driven by the increasing need to understand cellular heterogeneity in disease. Standard BioTools' C1 system and related IFCs position it to capitalize on this trend. The global single-cell analysis market is projected to reach $5.6 billion by 2027. By expanding its product offerings and applications in this area, Standard BioTools can significantly increase its revenue and market share.
- Penetration of the Proteomics Market: Proteomics is emerging as a critical field for understanding disease mechanisms and developing new therapies. Standard BioTools' mass cytometry and imaging systems are well-suited for proteomic analysis. The global proteomics market is expected to reach $42.7 billion by 2030. By focusing on developing proteomics-specific assays and workflows, Standard BioTools can tap into this high-growth market.
- Strategic Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies to develop novel diagnostic assays and companion diagnostics represents a significant growth opportunity. These partnerships can provide Standard BioTools with access to new markets and revenue streams. The companion diagnostics market is projected to reach $12.8 billion by 2028. Successful partnerships could drive significant revenue growth and enhance the company's reputation.
- Geographic Expansion into Emerging Markets: Expanding its sales and marketing efforts into emerging markets, such as China and India, can drive significant growth. These markets are experiencing increasing investment in life sciences research and clinical diagnostics. By establishing a stronger presence in these regions, Standard BioTools can tap into a large and growing customer base. Focus on these markets could yield substantial returns within the next 3-5 years.
- Development of Advanced Software Solutions: Enhancing its software capabilities to provide more comprehensive data analysis and visualization tools can improve the user experience and drive adoption of its systems. Advanced software solutions can also enable the development of new applications and workflows. Investing in software development and integration could lead to a competitive advantage and increased customer loyalty.
Opportunities
- Expansion in single-cell analysis
- Penetration of the proteomics market
- Strategic partnerships with pharmaceutical companies
- Geographic expansion into emerging markets
Threats
- Competition from larger companies
- Technological obsolescence
- Regulatory changes
- Economic downturns affecting research funding
Competitive Advantages
- Proprietary microfluidics technology
- Strong intellectual property portfolio
- Established relationships with leading research institutions
- High switching costs for customers due to integrated systems
About
Standard BioTools Inc., formerly known as Fluidigm Corporation, was founded in 1999 and is headquartered in South San Francisco, California. The company emerged from Mycometrix Corporation in April 2001, marking a strategic shift towards pioneering microfluidics and its applications in life sciences. Standard BioTools develops, manufactures, and markets a comprehensive suite of instruments, consumables, reagents, and software tailored for researchers and clinical laboratories globally. Their product portfolio includes analytical systems like the Helios CyTOF system and Hyperion imaging systems, crucial for advanced cellular analysis. They also offer preparatory instruments such as Juno systems, and analytical instruments like the Biomark HD and EP1 systems, which are essential for genomic and proteomic studies. Integrated fluidic circuits (IFCs) form a core part of their offerings, enabling efficient and precise sample processing. These IFCs support various applications, including library preparation, genotyping, and digital array analysis. The company's reagents and assays, such as Maxpar reagents and Advanta Dx SARS-CoV-2 RT-PCR assays, are designed to enhance the performance of their instruments. Standard BioTools serves a diverse customer base, including academic research institutions, translational research centers, cancer centers, clinical research laboratories, biopharmaceutical companies, and contract research organizations. The company has established license agreements with prestigious institutions like the California Institute of Technology and Harvard University, underscoring its commitment to innovation and collaboration.
What They Do
- Develops and manufactures analytical systems for biological research.
- Offers preparatory instruments for sample preparation.
- Provides integrated fluidic circuits (IFCs) for various applications.
- Markets reagents and assays for use with its instruments.
- Offers software solutions for data analysis and visualization.
- Serves academic research institutions and clinical laboratories.
- Supports biopharmaceutical and biotechnology companies.
Business Model
- Sells instruments and systems to research and clinical laboratories.
- Generates recurring revenue through the sale of consumables, reagents, and assays.
- Provides service and support for its installed base of instruments.
- Partners with pharmaceutical companies for assay development and commercialization.
Industry Context
Standard BioTools operates within the medical diagnostics and research industry, a sector characterized by rapid innovation and increasing demand for advanced tools and technologies. The global life science tools market is projected to reach $170 billion by 2028, driven by advancements in genomics, proteomics, and cell biology. Key trends include the growing adoption of single-cell analysis, spatial biology, and multi-omics approaches. The competitive landscape includes companies like ALIM (Alimera Sciences, Inc.), CLYM (Clal Biotechnology Industries Ltd.), CORBF (Corvus Pharmaceuticals Inc), INZY (Inozyme Pharma Inc), and LFCR (Lifecore Biomedical Inc), each with its own niche and technological focus. Standard BioTools differentiates itself through its integrated fluidic circuits and its expertise in mass cytometry and imaging.
Key Customers
- Academic research institutions
- Translational research and medicine centers
- Cancer centers
- Clinical research laboratories
- Biopharmaceutical and biotechnology companies
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $20M | -$35M | $-0.09 |
| Q2 2025 | $22M | -$33M | $-0.09 |
| Q1 2025 | $41M | -$26M | $-0.07 |
| Q4 2024 | $81M | -$85M | $-0.24 |
Source: Company filings
Chart & Info
Price Chart
Standard BioTools Inc. (FLDM) stock price: $3.70 (+0.00, +0.00%)
Why Bull
- •Recent insider buying suggests confidence in FLDM's future, indicating that those closest to the company believe in its potential.
- •Community sentiment has shifted positively, with discussions highlighting FLDM's innovative technologies and their impact on healthcare.
- •Analysts are noting FLDM's strategic partnerships, which could enhance its market reach and drive growth.
- •The recent focus on personalized medicine aligns with FLDM's offerings, positioning the company well in a growing market.
Why Bear
- •Concerns have been raised about FLDM's cash flow management, with some investors questioning sustainability in the current economic climate.
- •Bearish sentiment has emerged around potential regulatory hurdles that could delay product launches, impacting growth timelines.
- •Recent earnings calls revealed challenges in scaling operations, leading to skepticism about meeting future demand.
- •Market perception has been affected by broader economic uncertainties, causing some investors to adopt a cautious stance on FLDM.
Latest News
-
Earnings Scheduled For August 5, 2021
· Aug 5, 2021
-
56 Biggest Movers From Yesterday
· May 12, 2021
-
45 Stocks Moving In Tuesday's Mid-Day Session
· May 11, 2021
-
Earnings Scheduled For May 6, 2021
· May 6, 2021
Technical Analysis
Rationale
AI-generated technical analysis for FLDM including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Standard BioTools Inc. (FLDM) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for FLDM.
Make a Prediction
Set your price target for Standard BioTools Inc. (FLDM), choose a timeframe, and track your prediction accuracy.
Current price: $3.70
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FLDM.
Price Targets
Wall Street price target analysis for FLDM.
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 5/100
Revenue growth data is currently unavailable for this company.
-
Gross Margin 5/100
Gross margin data is currently unavailable for this company.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates FLDM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Standard BioTools Inc. do?
Standard BioTools Inc. is a life sciences company that develops, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories. The company's integrated systems empower scientists to accelerate discoveries and improve healthcare outcomes. Their product portfolio includes analytical systems like CyTOF and Hyperion imaging systems, preparatory instruments like Juno systems, and integrated fluidic circuits (IFCs) for various applications, including genomics, proteomics, and cell biology. They generate revenue through sales of instruments, consumables, and services to a global customer base.
Is FLDM stock a good buy?
FLDM stock presents a mixed investment profile. While the company's negative P/E ratio and profit margin raise concerns, its gross margin of 47.9% suggests underlying strength. The company's focus on high-growth areas like single-cell analysis and proteomics offers significant potential. Investors should consider the company's growth catalysts, such as strategic partnerships and geographic expansion, against the risks of competition and financial challenges. A balanced assessment of these factors is crucial before making an investment decision.
What are the main risks for FLDM?
The main risks for Standard BioTools include intense competition from larger companies with greater resources, the potential for technological obsolescence, dependence on research funding which can fluctuate with economic cycles, and ongoing financial challenges due to negative profitability and high operating expenses. Successfully navigating these risks is crucial for the company's long-term success. Investors should closely monitor these factors when evaluating the investment potential of FLDM.
Is FLDM a good stock to buy?
Whether FLDM is a good investment depends on your financial goals, risk tolerance, and investment horizon. Review the Investment Thesis, SWOT analysis, and Risk sections on this page. Always do your own research and consult a financial advisor before investing.
What is the FLDM MoonshotScore?
MoonshotScore is our proprietary AI-powered rating system that evaluates stocks based on growth potential, financial health, market momentum, and risk factors. It helps investors quickly identify high-potential opportunities. Check the MoonshotScore badge on this page for the current rating.
How often is FLDM data updated?
Stock prices are updated in real-time during market hours (9:30 AM - 4:00 PM ET). Company fundamentals, analyst ratings, and AI insights are refreshed daily. News is updated continuously throughout the day.
What are the growth catalysts for FLDM?
Growth catalysts vary by company and may include new product launches, market expansion, earnings surprises, partnerships, or industry tailwinds. Check the Catalysts section on this page for specific drivers relevant to Standard BioTools Inc..
Who are FLDM's main competitors?
Standard BioTools Inc.'s competitors depend on its industry and market segments. Check the Competitors section on this page for a list of direct competitors and how FLDM compares.
What do analysts say about FLDM?
Analyst ratings and price targets for FLDM are aggregated from multiple sources. Check the Analyst Consensus tab for buy/hold/sell ratings and the current consensus price target.
What is FLDM's market cap?
Market capitalization reflects the total market value of FLDM's outstanding shares. Check the Key Statistics section at the top of this page for the current market cap and other key financial metrics.
How has FLDM stock performed recently?
Check the Chart & Info tab for FLDM's recent price action, including daily, weekly, and monthly performance charts with technical indicators.
What are the risks of investing in FLDM?
Every stock carries risk. Check the Risks and Weaknesses sections on this page for FLDM-specific risk factors. Consider macroeconomic conditions, industry trends, and company-specific challenges.
Are insiders buying or selling FLDM?
Insider activity can signal management confidence. Check the Insider Flow tab for recent insider buys, sells, and exercise transactions for FLDM.
Is FLDM a good stock for beginners?
Standard BioTools Inc. (FLDM) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is FLDM for first-time investors?
Every stock carries risk, including Standard BioTools Inc. (FLDM). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like FLDM.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Stock data pending update.
- Financial metrics based on the most recent available data.